CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI
Нема приказа
Аутори
Životić, IvanĐurić, Tamara
Stanković, Aleksandra
Milašinović, Dejan
Stanković, Goran
Dekleva, Milica
Marković-Nikolić, Nataša
Alavantić, Dragan
Živković, Maja
Чланак у часопису (Објављена верзија)
,
© 2019 The Canadian Society of Clinical Chemists
Метаподаци
Приказ свих података о документуАпстракт
Background: Chromosomal region 9p21.3 is most robustly associated with coronary artery disease (CAD) in western European populations. However, heterogeneity in CAD phenotypes leads to uncertainty whether 9p21.3 is associated with stable and/or acute clinical presentations of CAD. 9p21.3 is rich in regulatory elements, but the underlying mechanisms of its actions in CAD remain unclear. We investigate the association of 9p21.3 two haplotype blocks lead variants (rs10757278 and rs518394) with first-ever non-fatal myocardial infarction (MI) in CAD patients and their association with CDKN2B mRNA expression in peripheral blood mononuclear cells 6 months after the event. Methods: We included CAD patients with sustained first MI (n = 523) and controls (n = 583). Gene expression was assessed in 72 patients 6 months after MI and 43 healthy controls. TaqMan® technology was used for the gene expression and genotyping analysis. Results: CDKN2B mRNA was significantly lower in MI patients compared wi...th the controls (p = 0.002) and in patients carrying the rs10757278 G risk allele versus AA homozygotes (p = 0.012) 6 months after the event. While we confirmed the association of rs10757278 with CDKN2B expression in MI patients, we failed to find an association between the investigated variants and MI or disease burden. Conclusions: We suggest a dysregulation of gene expression in the 9p21.3 region six months after acute MI, which is affected by a genetic variant in patients. The rs10757278 rare allele is one factor that might lead to prolonged risk for proatherogenic complications. © 2019 The Canadian Society of Clinical Chemists
Кључне речи:
Myocardial infarction / 9p21 / CDKN2B / rs10757278 / rs518394 / AtherosclerosisИзвор:
Clinical Biochemistry, 2019, 73, 70-76Финансирање / пројекти:
- Интегрална студија идентификације регионалних генетских фактора ризика и фактора ризика животне средине за масовне незаразне болести хумане популације у Србији - INGEMA_S (RS-41028)
- Генетска основа хуманих васкуларних и инфламаторних болести (RS-175085)
DOI: 10.1016/j.clinbiochem.2019.08.003
ISSN: 0009-9120
PubMed: 31386834
WoS: 000492745500010
Scopus: 2-s2.0-85070518697
Колекције
Институција/група
VinčaTY - JOUR AU - Životić, Ivan AU - Đurić, Tamara AU - Stanković, Aleksandra AU - Milašinović, Dejan AU - Stanković, Goran AU - Dekleva, Milica AU - Marković-Nikolić, Nataša AU - Alavantić, Dragan AU - Živković, Maja PY - 2019 UR - https://vinar.vin.bg.ac.rs/handle/123456789/8432 AB - Background: Chromosomal region 9p21.3 is most robustly associated with coronary artery disease (CAD) in western European populations. However, heterogeneity in CAD phenotypes leads to uncertainty whether 9p21.3 is associated with stable and/or acute clinical presentations of CAD. 9p21.3 is rich in regulatory elements, but the underlying mechanisms of its actions in CAD remain unclear. We investigate the association of 9p21.3 two haplotype blocks lead variants (rs10757278 and rs518394) with first-ever non-fatal myocardial infarction (MI) in CAD patients and their association with CDKN2B mRNA expression in peripheral blood mononuclear cells 6 months after the event. Methods: We included CAD patients with sustained first MI (n = 523) and controls (n = 583). Gene expression was assessed in 72 patients 6 months after MI and 43 healthy controls. TaqMan® technology was used for the gene expression and genotyping analysis. Results: CDKN2B mRNA was significantly lower in MI patients compared with the controls (p = 0.002) and in patients carrying the rs10757278 G risk allele versus AA homozygotes (p = 0.012) 6 months after the event. While we confirmed the association of rs10757278 with CDKN2B expression in MI patients, we failed to find an association between the investigated variants and MI or disease burden. Conclusions: We suggest a dysregulation of gene expression in the 9p21.3 region six months after acute MI, which is affected by a genetic variant in patients. The rs10757278 rare allele is one factor that might lead to prolonged risk for proatherogenic complications. © 2019 The Canadian Society of Clinical Chemists T2 - Clinical Biochemistry T1 - CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI VL - 73 SP - 70 EP - 76 DO - 10.1016/j.clinbiochem.2019.08.003 ER -
@article{ author = "Životić, Ivan and Đurić, Tamara and Stanković, Aleksandra and Milašinović, Dejan and Stanković, Goran and Dekleva, Milica and Marković-Nikolić, Nataša and Alavantić, Dragan and Živković, Maja", year = "2019", abstract = "Background: Chromosomal region 9p21.3 is most robustly associated with coronary artery disease (CAD) in western European populations. However, heterogeneity in CAD phenotypes leads to uncertainty whether 9p21.3 is associated with stable and/or acute clinical presentations of CAD. 9p21.3 is rich in regulatory elements, but the underlying mechanisms of its actions in CAD remain unclear. We investigate the association of 9p21.3 two haplotype blocks lead variants (rs10757278 and rs518394) with first-ever non-fatal myocardial infarction (MI) in CAD patients and their association with CDKN2B mRNA expression in peripheral blood mononuclear cells 6 months after the event. Methods: We included CAD patients with sustained first MI (n = 523) and controls (n = 583). Gene expression was assessed in 72 patients 6 months after MI and 43 healthy controls. TaqMan® technology was used for the gene expression and genotyping analysis. Results: CDKN2B mRNA was significantly lower in MI patients compared with the controls (p = 0.002) and in patients carrying the rs10757278 G risk allele versus AA homozygotes (p = 0.012) 6 months after the event. While we confirmed the association of rs10757278 with CDKN2B expression in MI patients, we failed to find an association between the investigated variants and MI or disease burden. Conclusions: We suggest a dysregulation of gene expression in the 9p21.3 region six months after acute MI, which is affected by a genetic variant in patients. The rs10757278 rare allele is one factor that might lead to prolonged risk for proatherogenic complications. © 2019 The Canadian Society of Clinical Chemists", journal = "Clinical Biochemistry", title = "CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI", volume = "73", pages = "70-76", doi = "10.1016/j.clinbiochem.2019.08.003" }
Životić, I., Đurić, T., Stanković, A., Milašinović, D., Stanković, G., Dekleva, M., Marković-Nikolić, N., Alavantić, D.,& Živković, M.. (2019). CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI. in Clinical Biochemistry, 73, 70-76. https://doi.org/10.1016/j.clinbiochem.2019.08.003
Životić I, Đurić T, Stanković A, Milašinović D, Stanković G, Dekleva M, Marković-Nikolić N, Alavantić D, Živković M. CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI. in Clinical Biochemistry. 2019;73:70-76. doi:10.1016/j.clinbiochem.2019.08.003 .
Životić, Ivan, Đurić, Tamara, Stanković, Aleksandra, Milašinović, Dejan, Stanković, Goran, Dekleva, Milica, Marković-Nikolić, Nataša, Alavantić, Dragan, Živković, Maja, "CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI" in Clinical Biochemistry, 73 (2019):70-76, https://doi.org/10.1016/j.clinbiochem.2019.08.003 . .